December 05, 2023
1 min watch
Save
VIDEO: Botensilimab plus balstilimab shows potential in sarcoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Sandra D’Angelo, MD, discussed a phase 1b study on the efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma presented at the Connective Tissue Oncology Society Annual Meeting.
“There was some efficacy described in leiomyosarcomas as well as visceral sarcomas, which is interesting considering some other efforts with monotherapy checkpoint blockade in these diseases. I look forward to hearing more about these two compounds,” D’Angelo, research director of the sarcoma medical oncology service at Memorial Sloan Kettering Cancer Center, told Healio.
Reference:
- Wilky BA, et al. Paper 31. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 1-4, 2023; Dublin.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
D’Angelo reports consulting/advising for Aadi Bioscience, Adaptimmune, Amgen, EMD Serono, GI Innovations, GSK, Immune Design, Immunocore, Incyte, Merck, Nektar, Pfizer, Rain Therapeutics and Servier; research funding from Amgen, Bristol Myers Squibb, Deciphera, EMD Serono, Incyte, Merck and Nektar; receiving travel/accommodations expenses from Adaptimmune, EMD Serono and Nektar; and being on a data safety monitoring board/advisory board for Adaptimmune, GSK, Merck and Nektar.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.